CL
ENGNW icon

CSS LLC’s enGene Therapeutics Warrants ENGNW Stock Holding History

CSS LLC’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9K Hold
16,895
– – ﹤0.01% 982
2026
Q1 		$42.7K Hold
16,895
– – ﹤0.01% 869
2025
Q4 		$50K Hold
16,895
– – ﹤0.01% 901
2025
Q3 		$12K Hold
16,895
– – ﹤0.01% 959
2025
Q2 		$13.9K Hold
16,895
– – ﹤0.01% 927
2025
Q1 		$10.1K Hold
16,895
– – ﹤0.01% 880
2024
Q4 		$14.2K Hold
16,895
– – ﹤0.01% 932
2024
Q3 		$32.9K Hold
16,895
– – ﹤0.01% 762
2024
Q2 		$20.1K Sell
16,895
-3,105
-16% -$9.94K ﹤0.01% 820
2024
Q1 		$104K Sell
20,000
-7,000
-26% -$21.3K 0.01% 705
2023
Q4 		$22.9K Buy
+27,000
New +$20.8K ﹤0.01% 747

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

CSS LLC's ENGNW Position: Q2 2026 in Review

CSS LLC held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 16,895 shares worth $4.9K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

CSS LLC first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $104K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • CSS LLC held 16,895 shares of enGene Therapeutics Warrants worth $4.9K as of Q2 2026.
  • CSS LLC left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of CSS LLC's portfolio in Q2 2026, its #982 holding.
  • CSS LLC first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
  • CSS LLC's enGene Therapeutics Warrants position peaked at $104K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.